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Abstract
Glutamate dehydrogenase 1 (GLUD1) is a mitochondrial enzyme expressed in all tissues,
including brain. Although this enzyme is expressed in glutamatergic pathways, its function as a
regulator of glutamate neurotransmitter levels is still not well defined. In order to gain an
understanding of the role of GLUD1 in the control of glutamate levels and synaptic release in
mammalian brain, we generated transgenic (Tg) mice that over-express this enzyme in neurons of
the central nervous system. The Tg mice have increased activity of GLUD, as well as elevated
levels and increased synaptic and depolarization-induced release of glutamate. These mice suffer
age-associated losses of dendritic spines, nerve terminals, and neurons. The neuronal losses and
dendrite structural changes occur in select regions of the brain. At the transcriptional level in the
hippocampus, cells respond by increasing the expression of genes related to neurite growth and
synapse formation, indications of adaptive or compensatory responses to the effects of increases in
the release and action of glutamate at synapses. Because these Tg mice live to a relatively old age
they are a good model of the effects of a “hyperglutamatergic” state on the aging process in the
nervous system. The mice are also useful in defining the molecular pathways affected by the over-
activation of GLUD in glutamatergic neurons of the brain and spinal cord.
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Introduction
Glutamate dehydrogenase1 (GLUD1) is a mitochondrial enzyme that is considered to be a
“housekeeping” protein involved in providing a substrate, α-ketoglutarate, to the
tricarboxylic acid cycle through oxidative deamination of glutamate. Liver GLUD has been
studied extensively with regard to the structure of the protein and the kinetic properties and
allosteric regulation of enzyme activity (Frieden 1959, 1965; Smith et al. 2001; Li et al.
2009). GLUD1 has been isolated from various tissues of different animal species, including
the human brain (Hussain et al. 1989). In the human brain, there are two forms of the
enzyme, GLUD1 and GLUD2, representing the products of two genes, one located on
chromosome 10 (Glud1) and the other on the X chromosome (Glud2) (Shashidharan et al.
1994). It has been suggested that the presence and expression in brain and retina of the
enzyme GLUD2, besides the “housekeeping” GLUD1, represents an evolutionary step that
provides for greater neurotransmitter (L-glutamate) flux and enhanced mental function in
humans and chimpanzees (Burki and Kaessmann 2004). The evolution of Glud2 is important
in determining the overall activity of the enzyme in brain and mutations in this gene may
lead to significant neurological diseases, as suggested by the fact that gain-of-function
mutations in Glud2 are linked to some cases of Parkinson’s disease (Plaitakis et al. 2010).
But, it may not only be GLUD2 that is of significance with regard to cognitive function in
mammals as the gene for Glud1 has also been identified as a memory-related gene in the
hippocampus (Cavallaro et al. 1997). Yet, the function of GLUD1 and GLUD2 in synaptic
transmission and, overall, in brain metabolism and physiology, is still not well characterized.
The GLUD proteins are distributed in regions of high glutamatergic neurotransmitter
activity in brain (Aoki et al. 1987; Kugler and Baier 1992; Bao et al. 2009a; Spanaki et al.
2010). Activation of the enzyme by the allosteric activator leucine, leads to increases in
glutamate flux in synaptosomes (Erecinska and Nelson 1990); this observation is suggestive
of a role for this enzyme in the control of glutamate levels at nerve terminals. The
deamination product of GLUD1 activity, α-ketoglutarate, would be expected to be the
predominant product of increased GLUD1 activity in neurons, and its transport out of
mitochondria and into the cytoplasm by the keto-dicarboxylic acid carriers of the
mitochondria would provide the substrate for transamination by aspartate aminotransferase
and the formation of glutamate that is stored and released by neurons (Palaiologos et al.
1989). Nevertheless, despite these observations, the potential role of GLUD activity in
neuronal synapses has remained poorly defined. In an effort to determine the function of
GLUD in neurotransmission, we developed transgenic (Tg) mice that over-express the
GLUD1 gene in central nervous system neurons only (Bao et al. 2009a). This was
accomplished by introducing the transgene under the control of the promoter for neuron
specific enolase (Nse). The results from such studies are outlined below.
Development and Characterization of Glud1 Tg mice
Enzyme expression and activity in brain
As reported previously (Bao et al. 2009a), the Glud1 Tg mice were generated by pronuclear
microinjections of mouse oocytes with a construct containing the cDNA for the mouse
Glud1 under the control of the Nse promoter. We identified four founder Tg mice that had
the Glud1 transgene and the gene-copy number in these mice was either 6 or 8 copies. The
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founder mice were mated with C57BL/6 wild type mice for over 10 generations. Inheritance
of the transgene has been that of a normal Mendelian transmission pattern (Bao et al.
2009a). In all studies that we have conducted, we have used only hemizygous mice and for
every characteristic that we have examined, we have not observed substantial differences
among the mice derived from the different founders.
The Nse gene is expressed only in neurons of brain and spinal cord (Peel et al. 1997) and in
studies with mice that we had generated and which had the transgene for Egfp under the
control of the Nse promoter, we found that EGFP fluorescence was highly enriched in
neuronal cell bodies and not in myelinated axonal tracks (Fig. 1). Therefore, we anticipated
that the Glud1 transgene expression would also be confined to neurons. Furthermore, as the
transgene for Glud1 includes the mitochondrial targeting sequence of the enzyme protein, it
was expected that the GLUD1 formed from the transgene would be localized in neuronal
mitochondria.
The levels of GLUD1 protein in homogenates from the brains of the Tg mice are
significantly higher (28.5 percent higher) than in littermate wt mice, as is also the GLUD
enzyme activity (35–40% higher in Tg vs. wt) (Bao et al. 2009a). Importantly, the GLUD
activity in the mitochondria and nerve-ending particle enriched P2 fraction isolated from
brain homogenates of Tg mice, has an estimated Vmax for L-glutamate deamination that is
significantly (65%) higher than that in wt P2. This enrichment in GLUD activity in the Tg
mouse was even more pronounced in the purified synaptosome fraction in which the Vmax is
153% higher in Tg than wt mice. The P2 fraction contains mitochondria derived from
neuronal and glial cell bodies, as well as from nerve endings, the higher Vmax in the Tg mice
is indicative of a greater enrichment of GLUD1 activity in neuronal tissue, an assertion that
is supported by the much higher Vmax in the isolated nerve ending particles (synaptosomes).
The synaptosome fraction represents an enriched preparation of intraneuronal mitochondria.
The KM values for GLUD activity do not differ significantly between Tg and wt mice for
either glutamate or NAD+ (Bao et al. 2009a).
In situ histochemical detection of GLUD activity in brain also indicates that known
glutamatergic regions of the brain, such as the pyramidal cell layer and dendritic fields of
the stratum oriens (SO) and stratum radiatum (SR) of the hippocampus CA1 and CA3
subfields, and the molecular layer of the dentate gyrus, are more strongly labeled in Tg mice
than the respective regions in wt mice (Bao et al. 2009a). The SO and SR fields of the
hippocampus are known to be enriched with glutamatergic nerve terminals thus the
histochemical labeling fits with the biochemical results of increased GLUD activity in
isolated nerve ending particles. Finally, immunohistochemical labeling with anti-GLUD1
antibodies reveals that in the strata of hippocampal pyramidal neurons of both CA1 and
CA3, GLUD1 immunoreactivity is significantly higher (53 percent higher) in Tg mice than
wt mice. Significantly increased levels of GLUD1 immunoreactivity in Tg (52 percent
higher) compared with wt mice was also detected in neurons of the cerebral cortex (Bao et
al. 2009a). The biochemical, histochemical, and immunocytochemical data are indicative of
overall increases in GLUD1 levels and activity throughout the brains of Tg mice and these
endophenotypic characteristics of the Glud1 Tg mice, plus the characteristics that will be
described below, are summarized in Table 1.
Glutamate levels and glutamate release in brain
Two important issues with regard to the Glud1 Tg mice are: a) whether Glud1 expression in
neurons leads to increases in brain concentrations of glutamate; and b) whether Glud1 over-
expression causes increased synaptic and post-depolarization release of glutamate. To
address the first issue, we determined whether Tg mice had higher levels of glutamate in
brain by using magnetic resonance spectroscopy (Bao et al. 2009a). Since glutamate may
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function as the precursor for other amino acids in brain (e.g., GABA and glutamine), we also
examined the concentrations of these amino acids in the hippocampus and striatum of Tg
and wt living mice. The concentration of glutamate in both brain regions is significantly,
though only modestly (9.76 μmol/mg in Tg vs. 8.99 μmol/mg in wt hippocampus; 8.87
μmol/mg in Tg vs. 8.01 μmol/mg in wt striatum), increased, the levels of GABA, aspartate,
and glutamine are not, and those of alanine are significantly decreased (0.56 μmol/mg in Tg
vs. 0.79 μmol/mg in wt hippocampus; 1.01 μmol/mg in Tg vs. 1.40 μmol/mg in wt striatum).
Thus, the expression of Glud1 in neurons of the Tg mice causes modest, yet significant,
increases in glutamate concentrations in brain without increasing GABA levels in inhibitory
neurons.
The exact compartment in which the increases in glutamate levels occur, i.e., glial vs.
neuronal, is not known. Glutamine levels in brain are primarily determined by glial cell
metabolism and, as we pointed out previously, the lack of a change in glutamine levels
might indicate that the increases in glutamate levels contribute a relatively small amount to
glial glutamine synthesis (Bao et al. 2009a). We also surmise that there is an increased rate
of conversion of neuronal glutamine to glutamate in neurons of the Tg mice thus
maintaining glutamine levels within a narrow range of concentrations. If this is the case,
then the elevated levels of NH4+ released as a result of increased glutamine to glutamate
conversion in neurons, may lead to reductive amination of α-ketoglutarate to glutamate and
thus elevations of neuronal glutamate (Bak et al. 2006). This may explain how increased
levels of glutamate in neurons may occur in the Glud1 Tg mice.
The decreased alanine levels, we hypothesize, might be the result of increases in the
transamination of excess α-ketoglutarate that is formed in mitochondria and transported to
cytoplasm. Increases in the cytoplasmic levels of α-ketoglutarate may lead to enhanced
transamination by alanine aminotransferase and the formation of glutamate and pyruvate
(Bak et al. 2006). The glutamate formed may be stored in synaptic vesicles in neurons of the
Tg mouse brain. These are complex metabolic pathways that have not yet been explored in
the Tg mice. The measurements that were obtained were not designed to label and monitor
the metabolic inter-conversions of glutamate and its metabolites through various metabolic
pools but rather to estimate the steady state levels of these amino acids that are related to
glutamate metabolism.
Increases in glutamate levels in the brains of Tg mice, even if they are occurring within
neurons, may not, necessarily, reflect increases in pools of glutamate at synapses and which
may be released following neuronal depolarization. For this reason, we undertook, first, the
measurement of depolarization-induced release of glutamate. Using self-referencing
microelectrode arrays, we measured glutamate release and clearance in vivo in the striatum
of Tg and wt mice. Depolarization-induced release was evoked by local injections of
nanoliter volumes of 70 mM KCl. The application of 70 mM KCl for 1–2 sec produced
rapid and reproducible changes in extracellular glutamate concentrations and this
depolarization-induced release of glutamate is consistently and significantly higher in Tg
mice (Bao et al. 2009a). Almost identical volumes (135–140 μL) of KCl applications in Tg
and wt mice produce a 57% higher level of glutamate release in Tg vs. wt mouse striata. It is
important to note that the higher amplitude of glutamate release in Tg as compared with wt
mice is not the result of any deficits in glutamate uptake by glia or neurons. The clearance
rates of depolarization-induced glutamate release are almost identical in Tg and wt mice. In
addition, nearly identical kinetics for glutamate clearance from the extracellular space are
measured following local application of nanoliter volumes of 5 mM glutamate in the
striatum of Tg and wt mice. These results are confirmatory of the assertion that the kinetics
of glutamate transport into glia and neurons are as rapid and effective in Tg as in wt mice.
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Thus, changes in glutamate transport cannot explain the higher levels of released glutamate
following a depolarizing stimulus.
To determine whether the increased release of glutamate following neuronal depolarization
is due to excess release of neurotransmitter at known excitatory glutamatergic synapses, we
measured both the amplitude and frequency of miniature excitatory currents (mEPSCs) in
synapses of the CA1 subfield of the hippocampus. Based on studies in other species, such as
Drosophila (Daniels et al. 2004), increased amounts of glutamate in synaptic vesicles, as
might be occurring also in Glud1 Tg mice, would be expected to lead to increases in both
mEPSC frequency and amplitude. The frequency of mEPSCs measured in CA1 excitatory
synapses is increased by an estimated 500 percent in Tg vs. wt mice, and the amplitude by
100 percent (Bao et al. 2009a). Thus, the Glud1 Tg mice exhibit both increased spontaneous
synaptic and depolarization-induced neuronal release of glutamate; but, because of normally
functioning glutamate transport processes, the increases in extracellular glutamate levels are
probably rapidly dissipating. Based on these observations, we conclude that the activity of
the mitochondrial enzyme GLUD contributes to the maintenance of glutamate
neurotransmitter pools at the synapses of glutamatergic neurons.
Glud1 Tg mice as models of age-associated neuronal degeneration
Neuronal structure in the brain of Tg mice
Assuming that the enhanced release of glutamate from neurons occurs in the Tg mice across
the life-span of these animals, this characteristic makes these mice a useful model for studies
focused on the effects of transient hyper-glutamatergic states in brain on neuronal structure
and function during development as well as aging. In histological sections from the CA1
region of the hippocampus, the ventral dentate gyrus, and layers III to V of the primary
motor/somatosensory cerebral cortex of 12–20 month old mice, we observed significant
decreases in the number of neurons in Tg vs. wt mouse brains (Bao et al. 2009a). Besides the
decreases in certain types of neurons in hippocampus and cerebral cortex, many neurons are
shrunken and darkly stained (pyknotic). Such morphological changes have been described
previously for neurons exposed to high levels of glutamate resulting from inhibition of
glutamate transporters (Arias et al. 1997), thus linking the increased release of glutamate in
the Glud1 Tg mice to the neuronal losses observed in select regions of the brain.
The losses of large pyramidal neurons observed in the cortex and hippocampus of Tg mice
appear to be rather selective in nature as we did not observe losses of other large brain
neurons, such as the Purkinje neurons of the cerebellar cortex. In addition to the selective
loss of neurons in the brain of Tg mice, we also observed losses among the population of
large motor neurons in the ventral horn of the cervical and lumbar spinal cord of Glud1
mice, 16 months old or older, when compared with wt mice of the same age (Fig. 2).
Surviving motor neurons in the spinal cord appear to be shrunken and stain weakly with
methylene blue. Unlike the ventral horn motor neurons, most neurons of the intermediate
nucleus of the spinal cord appear to be surviving in Glud1 mice, although they stain less
strongly than in wt mice.
In addition to the neuronal losses observed in select regions of the brain, neurons in
hippocampus, cerebral cortex, and striatum of Glud1 mice exhibit an overall significant
decrease in dendrite labeling by anti-microtubule-associated protein 2A (MAP2A)
antibodies (Bao et al. 2009a). Decreases in dendrite labeling are pronounced in the CA1
subfield of the hippocampus but not in the CA3 subfield, a further indication of the selective
nature of neuronal changes occurring in the brain of Glud1 mice. We noted that the
decreases in anti-MAP2A labeling in dendrites of CA1 pyramidal neurons of Glud1 mice are
similar to the decreases in MAP2A labeling in the hippocampus of rats following the
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injection of dihydrokainate, a glutamate transporter inhibitor (Zhang et al. 2007). In both the
CA1 neurons of Glud1 Tg mice and those in the hippocampus of animals treated with an
inhibitor of glutamate transporters, the cell bodies of the neurons are, generally, well-labeled
by anti-MAP2A antibodies, i.e., there is continued synthesis of MAP2A in neuronal cells of
Glud1 mice or in rats injected with dihydrokainate (Arias et al. 1997). These observations
are strongly suggestive that a state of hyper-glutamate release in Glud1 Tg mice is the likely
cause of the decreases in MAP2A labeling in dendrites of the CA1 field of the hippocampus.
Another observation made with regard to neuronal structure of the Glud1 Tg mice is that in
areas of the hippocampus with significant loss of neurons and reduction of dendrite labeling
by anti-MAP2A, there is also a significant decrease in axonal nerve terminal labeling with
anti-synaptophysin antibodies (double immune labeling) when compared with the labeling
observed in wt mice (Bao et al. 2009a). It is important to note, however, that the loss of
nerve terminals in Tg mice is not a universal phenomenon in brain as losses of
synaptophysin labeling are not apparent in the striatum of Tg mice.
We used a method of double-labeling of neurons with anti-MAP2A antibodies and the
carbocyanine dye DiI, a cell membrane-labeling dye, in order to examine the integrity of
neuronal dendrites and dendritic spines in susceptible regions of the Tg mouse brain, the
CA1 and cortical regions. This double-labeling approach revealed that despite the
discontinuities and decreases in dendrite labeling by anti-MAP2A antibodies in the Tg
mouse brain, the labeling by DiI is indicative of intact membrane structure in the primary
dendrites of these same neurons (Bao et al. 2009a). The DiI labeling, however, does reveal a
significant loss of dendritic spines in CA1 neurons, especially of mushroom and stubby
types of synapses. These types of synapses, especially the mushroom type, are important in
the establishment and maintenance of long term potentiation of synaptic activity (Matsuzaki
et al. 2004).
Aging, neuronal loss and changes in dendritic structure and function
It has been observed that synaptic and neuronal losses during the aging process, both in
human and rodent brains, occur along pathways of glutamatergic neurotransmission (Terry
et al. 1987; Masliah et al. 1993; Jacobs et al. 1997; Francis 2003; Morrison and Hof 2007).
The brain regions where synaptic and neuronal losses have been observed include those of
the hippocampus and cerebral cortex, regions that are also affected in the Glud1 Tg mice.
The loss of synapses and neurons in these regions of the rodent brain may also correlate with
the observed age-associated increases in extracellular glutamate resulting from diminished
glutamate transport into neurons or glial cells during the aging process (Wheeler 1980;
Freeman and Gibson 1987; Najlerahim et al. 1990; Massieu and Tapia 1997; Zoia et al.
2004; Nickell et al. 2005). In our studies, MAP2A labeling of cell bodies and dendrites of
the CA1 region of the hippocampus was used to measure changes in the numbers of neurons
and in dendritic structure with advancing age (Bao et al. 2009a). In Tg mice between the
ages of 6 and 20 months, both the number of neurons and the labeling of dendrites is
decreasing significantly with advancing age. In wt mice of identical ages, there is no
significant trend of either neuronal loss or dendritic loss. A detectable decrease in MAP2A
labeling of cell bodies and dendrites was observed in wt mice between the ages of 11 and 20
months. However, there is no statistically significant pattern of decreased labeling across the
age span from 6 to 20 months for either neuronal cell body labeling or dendrite labeling in
the wt mice. We did note, though, that the rates of decrease in MAP2A labeling between 11
and 20 months in both wt and Tg mouse CA1 are very nearly equal. Thus, even though the
trends of age-associated decreases from 6 to 20 months are significant only in Tg mice, the
decreases in MAP2A labeling between 11 and 20 months in wt mice might indicate that the
over-expression of Glud1 and the resulting excess in glutamate release in Tg mice,
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accelerate a trend of age-related cell loss and altered dendrite structure in the CA1 region of
the hippocampus.
We assume that these changes in the wt mice are occurring as a result of diminished
glutamate transport and the increased accumulation of extracellular glutamate with
advancing age, and that the effects of such glutamate hyperactivity are enhanced by the
excess release of glutamate in the Tg mice. Such enhanced activity of glutamate in the
extracellular space occurring even at young ages would explain the significant decreases in
cell and dendrite labeling of Tg mice at 6, 11, and 20 months when compared with the wt
mice. And, as described above, the age-associated effect of Glud1 over-expression on
neuronal population numbers and dendrite structure is not manifested to any degree in the
CA3 region of the hippocampus, a further indication of true selective vulnerability of
neurons to the aging process and to the over-production and release of glutamate.
An important issue with regard to the losses in neurons and dendritic processes in Tg mice is
the possible functional consequences of these structural changes. We have observed that the
slope of field-evoked excitatory postsynaptic potentials (fEPSP) is significantly lower in
hippocampal CA1 neurons from Tg vs. wt mice, and that the lower fEPSP slopes in Tg mice
are evident during both the initial period as well as the sustained period of LTP (Bao et al.
2009a). The initial transient phase of LTP is apparently dependent on signals that enhance
neurotransmitter release from pre-synaptic terminals over a prolonged period of time,
whereas the sustained component of LTP is due to receptor changes at the post-synaptic
sites (Volianskis and Jensen 2003). It is possible that in the Tg mice both components of
LTP are altered because of decreases in the number of glutamatergic nerve terminals and of
dendritic spines with which they make synapses. An alternative explanation might be that
both phases of LTP are affected by an altered expression of certain genes and of the
respective proteins, especially genes and proteins that have important functions in
establishing LTP, such as the N-methyl-D-aspartate (NMDA) and the α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) type of glutamate receptors, or the
various regulators of presynaptic glutamate release during LTP, such as glycogen synthase
kinase 3 beta (GSK3β).
Whole genome transcriptional activity in Glud1 Tg mice: Adaptive or
compensatory responses to a chronic hyperglutamatergic state
In order to address the issue of differential expression of certain genes in Tg vs. wt mice, we
performed an analysis of genome-wide expression in nine month-old Glud1 and wt mice
(Wang et al. 2010). We selected the 9 month age because at that age the Tg mice exhibit
moderate losses of neurons and dendritic processes, thus making it possible to probe for
changes in gene expression in neurons and glia with minimized distortion of the results by
excessive neuronal death. The microarray data from the Tg and wt mice fall into two distinct
clusters, one corresponding to the group of Tg and the other to that of the wt mice. There are
707 probesets that are significantly more highly expressed in Tg than wt mice (up-
regulated), and 311 that are significantly down-regulated in Tg vs. wt mice.
Gene Ontology (GO) analyses identified biological processes that are significantly enriched
in up-regulated or down-regulated genes. The genes within these GO categories (Table 2
and also Fig. 3) fall into eight biological processes; four of the GO biological processes,
those of Nervous system development, Intracellular signal transduction, Synaptic
neurotransmission, and Ion homeostasis, are enriched in both up- and down-regulated genes,
while four others, those of mRNA processing, Protein mis-folding correction and
degradation, Cytoskeleton and focal adhesion, and Cognition and behavior, contain only
significantly up-regulated genes in Tg mice. Pathway analysis of the gene expression data
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identified similar biological functions to those uncovered using GO analyses (Wang et al.
2010). However, some new pathways were also uncovered, such as those enriched with
genes involved in oxidative stress responses and inflammation.
Neuronal growth, differentiation and preservation of synaptic transmission are among the
GO categories and pathways that are enriched with genes differentially expressed in Tg
mice. The genes in these categories are mostly up-regulated in the hippocampus of Tg mice
and are related to growth of nerve processes, differentiation of neurons, synapse formation,
and synaptic transmission. Genes of importance with regard to neuro-transmission include
two of the most up-regulated genes in Glud1 mice, those for the NMDA receptor subunits
2A and 2B (Grin2A and Grin2B). In addition to the up-regulation of expression of the
NMDA receptor genes, the genes for three other glutamate receptors, Gria1 (Glutamate
receptor ionotropic AMPA subunit 1), Gria3 (AMPA receptor subunit 3), and Grik2
(Glutamate receptor ionotropic kainate subunit 2), were also up-regulated, although not to
the same level as the NMDA receptor genes. The differential level of expression of the
glutamate receptor genes contributed to the identification of the pathway Synaptic long term
potentiation as one that is significantly enriched with up-regulated genes (Table 2). Based
on the gene expression patterns for glutamate receptors, some of which have been confirmed
at the protein level by immunoassays (Wang et al. 2010), the decreases in LTP in the Tg
mice are more likely to be related to nerve ending and spine losses than decreases in the
levels of glutamate receptors.
The increased expression of NMDA receptor genes is, most likely, linked to growth of new
synapses as a compensatory response in neurons of the Tg mouse hippocampus to the
damage to dendrites and nerve terminals described above. Such an interpretation is
supported by the observed increases in gene expression in Tg mouse hippocampus for the
synaptic membrane scaffold proteins (Dlg1, Dlg2, and Dlg4), for a protein associated with
the strengthening of synapse function (Arc, Activity-Regulated Cytoskeleton-Associated
Protein), and for genes that determine axon, dendrite and synapse growth, including four
genes for the ephrin receptors, the gene for brain-derived neurotrophic factor (BDNF), and
those for two neurotrophic factor receptors, NTRK2 and NTRK3.
Increased expression in the hippocampus of Glud1 mice of another group of genes with
implications for neurite elongation and synapse formation is that represented by the category
of Cytoskeleton and focal adhesion. We constructed a schematic gene network for the genes
that are involved in neurite growth and synapse formation and that are up-regulated in Tg
mice (Fig. 4). In this network, we included proteins involved in focal adhesion of cell
membranes to the extracellular matrix, such as the focal adhesion tyrosine kinase Ptk2b, as
well as genes for the organizing elements of the cytoskeleton, such as the gene for the actin-
organizing protein Arpc2 (Actin related protein 2/3 complex subunit 2). The gene-gene
interactions displayed in this network are based on previous experimental evidence from the
literature. The increases in expression of some of these genes have been confirmed by PCR
(for mRNA) and immunochemical or immunohistochemical methods (for the respective
proteins) (Wang et al. 2010). We are currently exploring the idea that changes in the
expression of the genes described above are a compensatory response to loss of neurites and
synapses throughout the lifespan of the Tg mice by examining the changes in gene
expression in Tg and wt mice from 10 days to 20 months of age. Starting the examination of
gene expression changes at a very young age (10 days), we may be able to distinguish
changes in gene expression due to neuronal damage during development from those that
represent compensatory or adaptive changes in neurons or glial cells during the life of the Tg
mice.
Michaelis et al. Page 8













A prominent example of differential gene expression in Tg mice that represents a
compensatory response to a hyperglutamatergic state is the up-regulation of genes for the
glutamate transporters, such as Slc1a2, the predominant transporter in the plasma
membranes of glial cells (Lehre and Danbolt 1998), and Slc1a1, the neuronal glutamate
transporter. The up-regulation of the latter transporter was confirmed by immunochemical
assessment of the expression of the respective protein, and by measurements of neuronal
glutamate uptake activity in vitro (comparative measurements of radioactive glutamate
uptake by synaptosomal preparations of wt and Tg mice) (Wang et al. 2010). These
measurements confirmed the fact that these gene and protein changes are linked to
functional compensation for the higher levels of glutamate release from nerve terminals in
Tg vs. wt mice.
Conclusions
The development of the Tg mouse that over-expresses the gene for Glud1 in neurons of the
central nervous system was undertaken in order to determine the role of the enzyme GLUD1
in the maintenance of glutamate neurotransmitter levels in brain and, hopefully, to provide
an animal model that exhibits lifelong, moderate excess formation and release of glutamate.
Animal models of excess glutamate accumulation in the extracellular space have been
generated previously through down-regulation or targeted disruption of glutamate
transporters. These animal models include the Slc1a2 and Slc1a3 glutamate transporter null
mutants, and the Tsc1 (Tuberous Sclerosis 1) knockout mice. All of these mice accumulate
high levels of extracellular glutamate and this leads to the disruption of normal brain
development, lethal spontaneous seizures, extensive neuronal death, and severely shortened
lifespan (Rothstein et al. 1996; Tanaka et al. 1997; Matsugami et al. 2006; Zeng et al. 2007).
In other words, these three types of mice, as the homozygous mutants, are not appropriate
for the study of the effects of lifelong, pulsatile, moderately excessive glutamate release at
neuronal synapses on nervous system structure and function. On the other hand, the
heterozygous mice for the null mutation of Slc1a3 do survive to approximately the same age
as wild type mice, have no morphological changes in the brain, and exhibit only modest
differences in behavior, such as increased locomotor activity(Kiryk et al. 2008). But, to this
date, there are no reports of changes in synaptic transmission in the heterozygous null
mutant mice nor are there reports of age-dependent brain anomalies exhibited by these mice.
The over-expression of Glud1 in the Tg mice we created does result in moderate excess
formation and synaptic release of glutamate and is compatible with a long life of the
heterozygous Glud1 Tg mice. As described above, the Glud1 Tg mice suffer relatively
confined structural and functional damage in their brain and spinal cord and the loss of
neurons, dendritic spines, and nerve endings during the aging process. The latter changes
seem to parallel some of the neuronal and synaptic losses observed in human brain during
aging. The moderate and selective nature of neuronal damage in Glud1 mice probably
accounts for the survival of these mice into early stages of aging. However, despite the
observed changes in synaptic glutamate release, dendrite and spine morphology, and LTP
formation, these Tg mice do not exhibit deficits in learning new behaviors (Bao et al. 2009b)
or in memory formation of learnt behaviors (R. Pal and E. Michaelis, unpublished
observations). These are unexpected results as the assumption has been that neuronal
damage in the hippocampus and decreases in LTP formation would result in deficits in
learning and memory. It is possible, however, that the relationship between glutamate
neurotransmission in the hippocampus and learning and memory formation are not as tightly
linked as has been thought. Mice that have genetic knockdown for the gene of phosphate-
activated glutaminase (Gls1), have significantly decreased glutamate levels in the
hippocampus and significantly lower levels of glutamate release at glutamatergic synapses
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in the hippocampus CA1 region, yet they exhibit normal spatial learning and memory
retention of the learnt behaviors (Gaisler-Salomon et al. 2009).
Up until now, most of the ideas about glutamate hyperactivity have been based on results
from acute exposure of neurons, either in vitro or in vivo, to sudden large excesses of
extracellular glutamate or one of its congeners, such as NMDA (Buddle et al., 2003;
Hoskison et al., 2007). Studies such as those cited here, and many others, have led to the
expectation that all neurons in brain or spinal cord would suffer severe injury and cell death
following exposure to increased extracellular glutamate concentrations. Such assertions have
been supported by the previously developed animal models of excess extracellular
glutamate, that is, those with down-regulation or targeted disruption of glutamate
transporters described above. However, assumptions made on the basis of massively
destructive effects due to large increases in extracellular glutamate may have to be revised
upon better understanding of the more subtle effects on neuronal structure and physiology,
as well as organismal biology and behavior, produced by moderate, pulsatile increases in
synaptic glutamate release throughout the lifespan of an organism. For example, the
selective synapse and neuronal losses observed in the Glud1 Tg mice, would not have been
predicted if one focused only on models of glutamate-induced excitotoxicity brought about
by large, excessive concentrations of extracellular glutamate. In support of the idea that
excess glutamate release or accumulation in the extracellular space may lead to selective
neuronal damage are the observation of a relative degree of selectivity in neuronal injury,
such as that of neurons in layer II of the cortex and the CA1 region of the hippocampus, in
null mutant Slc1a3 mice (Kiryk et al. 2008). Thus, the selective nature of neuronal and
synaptic losses that are observed along select glutamatergic pathways in human brain during
the aging process and in some neurodegenerative diseases, might indeed be explained as
phenomena related to glutamate transmitter hyperactivity. And, we believe that the Tg mice
we created are good models of such selective neuronal vulnerability to glutamate over-
activity and may be used to uncover the molecular pathways that determine these selectively
expressed changes in populations of neurons.
Another phenomenon that would have been difficult to predict on the basis of studies
examining the toxic effects of large concentrations of glutamate would have been the type of
up-regulation of gene transcription and protein levels of components of the neurite
elongation and synapse formation pathways that we observed in the Glud1 Tg mice. Acute
experimental manipulations leading to excitotoxicity do not provide an appropriate
environment for the detection of compensatory or adaptive responses to glutamate-induced
neuronal injury that may occur over a prolonged period of time. On the other hand, the 9
month old Glud1 Tg mice that have to cope with moderate increases in mitochondrial
GLUD activity and synaptic glutamate release, do exhibit a significant up-regulation of gene
and protein components that are part of signaling cascades and mechanical aspects of nerve
process growth and synapse formation. Furthermore, some of the adaptive changes involved
in synapse formation, such as the increased expression of various sub-types of glutamate
receptors, would have been considered as unlikely processes to be up-regulated in a pure
“excitotoxicity model” of glutamate hyperactivity in the brain (up-regulation of glutamate
receptors would seem counterproductive as a response to excitotoxicity). In conclusion, the
Glud1 mice offer a potentially useful animal model for the study of the role of the enzyme
GLUD in the central nervous system, for exploring the direct and indirect effects of
moderate excess of glutamate transmitter release in the nervous system, for examining the
aging-related aspects of glutamate hyperactivity in brain, and for delving into the molecular
and cellular pathways that lead to adaptive or compensatory neuronal responses to excess
glutamate and which may be exploited in developing methods for suppression of neuronal
damage or loss in neurodegenerative diseases.
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fEPSPs fast excitatory postsynaptic potentials
GABA γ-aminobutyric acid
Glud1 glutamate dehydrogenase 1
MAP2A microtubule-associated protein 2A
mEPSCs miniature excitatory postsynaptic currents
NMDA N-methyl-D-Aspartate
Nse neuron-specific enolase
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Expression pattern of EGFP in a transgenic mouse generated with the Egfp gene under the
control of the Nse promoter. EGFP fluorescence in corpus callosum (CC) and striatum (Str)
of a hemizygous Tg mouse is shown. Note the lack of, or low levels of, EGFP fluorescence
in myelinated tracks, such as those in the CC and in part of corona radiata (CR). Line: 10 μm
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Large motor neuron loss in the ventral horn of the cervical spinal cord of a Glud1 Tg (B, D)
as compared with a wt mouse (A,C). Both mice were of the same age (17 months). C, D:
magnification of ventral horn from A and B.
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A schematic depiction of the relationships of neurons, astrocytes, and microglial cells with
respect to the major GO categories of genes that are differentially expressed in the Glud1 Tg
vs. those in the wt mouse hippocampus. The GO categories are also summarized in Table 2.
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Scheme of a hypothesized network of genes involved in nerve process elongation and
synapse formation, genes whose expression is up-regulated in Glud1 Tg mice. Depicted in
this scheme is the tip of a hypothetical growth cone and the genes involved in nerve process
elongation and synapse formation. The genes were grouped based on their function: b1 -
growth factor and ephrin receptors; b2 - glutamate receptor and scaffolding genes; b3 -
extracellular matrix interacting genes (integrin); b4 - actin-organizing genes; b5 - focal
adhesion complex genes; and b6 - signal transduction genes. Interactions among the genes
shown are portrayed by lines connecting individual genes. Such interactions were culled
from previously published studies. Only genes that were up-regulated in Glud1 as compared
with wt mouse hippocampus and that are related to neurite growth and synapse formation
are shown in this scheme. The figure is reproduced from Wang et al. BMC Genomics 2010,
11:360.
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Table 1
Differential Characteristics of Glud1 Tg Mice Compared with wt C57Bl/6 mice
Biochemical and Cellular Characteristics Brain Region/Subcellular Fraction Tg vs. wt (↑-increase; ↓-decrease; →-no change)
GLUD Activity (Biochemical) Whole brain homogenate ↑
Whole brain P2 ↑↑
Whole brain synaptosomes ↑↑↑
GLUD Activity (Histochemical) Hippocampus ↑↑




Glutamate Levels Striatum ↑
Hippocampus ↑




Spinal Cord Motorneurons ↓↓




Depolarization-induced Glutamate Release Striatum ↑↑
Synaptic Glutamate Release CA1 Hippocampus ↑↑↑
Spine Density CA1 Hippocampus ↓↓
Synaptophysin Labeling of Nerve Terminals CA1 Hippocampus ↓↓
Transient and Sustained LTP CA1 Hippocampus ↓↓
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Table 2
Biological Processes and Canonical Pathways identified by transcriptomic assays as being enriched with genes
that are either up-regulated or down-regulated in Glud1 Tg mice when compared with wt littermates.
GO Biological Processes Canonical Pathways
Nervous system development Axonal Guidance Signaling
Up-regulated genes (70); Up-regulated genes (23)
Down-regulated (29) Down-regulated genes (10)
Intracellular signal transduction Neurotrophin/TRK Signaling
Up-regulated (68) Up-regulated genes (6)
Down-regulated genes (57) Down-regulated genes (1)
Synaptic neurotransmission Synaptic Long Term
Up-regulated genes (21) Potentiation
Down-regulated genes (10) Up-regulated genes (9)
Down-regulated genes (2)
Ion transport & homeostasis Ephrin Receptor Signaling
Up-regulated genes (23) Up-regulated genes (14)
Down-regulated genes (4) Down-regulated genes (6)
mRNA processing Integrin Signaling
Up-regulated genes (15) Up-regulated genes (12)
Protein mis-folding correction & degradation Huntington’s Disease Signaling (Axoplasmic transport-related)
Up-regulated genes (9) Up-regulated genes (17)
Down-regulated genes (5)
Cytoskeleton & focal adhesion Neuregulin Signaling
Up-regulated genes (38) Up-regulated genes (7)
Down-regulated genes (1)
Cognition & behavior NRF2-mediated Oxidative
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